Mutual of America Capital Management LLC Has $1.72 Million Holdings in Enovis Co. (NYSE:ENOV)

Mutual of America Capital Management LLC lowered its stake in shares of Enovis Co. (NYSE:ENOV) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,674 shares of the company’s stock after selling 1,562 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Enovis were worth $1,718,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ENOV. UMB Bank n.a. bought a new position in shares of Enovis during the 3rd quarter worth about $31,000. Fifth Third Bancorp grew its position in Enovis by 144.6% during the third quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock worth $31,000 after buying an additional 347 shares in the last quarter. State of Wyoming increased its stake in Enovis by 59,200.0% during the fourth quarter. State of Wyoming now owns 593 shares of the company’s stock valued at $32,000 after acquiring an additional 592 shares during the period. First Horizon Advisors Inc. raised its holdings in Enovis by 902.7% in the 3rd quarter. First Horizon Advisors Inc. now owns 732 shares of the company’s stock valued at $39,000 after acquiring an additional 659 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of Enovis in the 4th quarter worth approximately $63,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Trading Up 1.0 %

Shares of ENOV stock opened at $55.83 on Monday. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $3.06 billion, a P/E ratio of -91.52 and a beta of 1.97. Enovis Co. has a 12-month low of $43.04 and a 12-month high of $66.14. The firm has a 50-day moving average price of $60.29 and a 200 day moving average price of $55.36.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The company had revenue of $455.00 million during the quarter, compared to analysts’ expectations of $444.34 million. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. Enovis’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.72 earnings per share. Research analysts forecast that Enovis Co. will post 2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ENOV. Wells Fargo & Company boosted their price objective on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. William Blair initiated coverage on shares of Enovis in a report on Wednesday, January 3rd. They set an “outperform” rating for the company. Canaccord Genuity Group lifted their target price on shares of Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price target on shares of Enovis in a research report on Wednesday, April 10th. Finally, Stephens initiated coverage on Enovis in a report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.